PTC Will Work With Roche And Celgene | September 7, 2009 Issue - Vol. 87 Issue 36 | Chemical & Engineering News
Volume 87 Issue 36 | p. 30 | Concentrates
Issue Date: September 7, 2009

PTC Will Work With Roche And Celgene

Department: Business
Keywords: PTC, Celgene, Roche, small molecule

PTC Therapeutics has signed a research and licensing agreement with Roche for the development of small molecules with PTC’s Gene Expression Modulation by Small-Molecules, or GEMS, technology. Roche will pay PTC $12 million up front and could pay up to $239 million for each of four central nervous system disease targets if milestones are met. Separately, PTC will apply the GEMS technology to a Celgene oncology drug target. Celgene acquired an option for the research when it invested $20 million in PTC in 2007.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment